Exchanges
BSE, NSE
Industry
Pharmaceuticals
Issue
Book building

Eris Lifesciences IPO

₹601.50

−0.25% on listing

Listing-day close · NSE · 29 Jun 2017 · issue price ₹603

Eris Lifesciences’ ₹1,740 crore IPO was priced at ₹603 a share. It listed on the NSE on 29 Jun 2017 and closed its first day at ₹601.50, down 0.25% on the issue price.

Timeline

  1. Opens
  2. Closes
  3. Allotment
  4. Refunds
  5. Shares in demat
  6. Listing

Issue details

Issue size
₹1,740 Cr
Fresh issue
—
Offer for sale
₹1,740 Cr
Lot size
24 shares
Minimum investment
₹14,472
Face value
₹1
Registrar
MUFG Intime India

Subscription

Eris Lifesciences IPO subscription by investor category
CategoryShares offeredTimes subscribed
Total—2.25×

Overall, from the basis of allotment.

Financials and valuation

Market cap (post-issue)
₹8,291 Cr
Promoter holding
59.18% → 55.93%

From the offer documents.

Listing

Listing date
29 Jun 2017
Issue price
₹603
Open
₹611.00
High
₹628.00
Low
₹593.25
Close
₹601.50

Listing day on the NSE. The close was −0.25% on the issue price.

ERIS share price today

FAQs

When did the Eris Lifesciences IPO open and close?

It opened on 16 Jun 2017 and closed on 20 Jun 2017.

What was the Eris Lifesciences IPO price?

The price band was ₹600–603 a share. The final issue price was ₹603.

What is the lot size and minimum investment?

One lot is 24 shares, ₹14,472 at ₹603 a share. Retail investors apply in whole lots.

How much did Eris Lifesciences raise?

₹1,740 crore: ₹1,740 crore offered by existing shareholders.

How many times was the Eris Lifesciences IPO subscribed?

2.25 times overall.

How did Eris Lifesciences list?

It listed on the NSE on 29 Jun 2017 at ₹611.00 and closed the day at ₹601.50, down 0.25% on the ₹603 issue price.

Who is the registrar of the Eris Lifesciences IPO?

MUFG Intime India handles the allotment, refunds and credit of shares.

For information only. Not investment advice or a research report.

Full disclaimer

See how an IPO fits your plan

Armor checks every holding against your goals, risk and timeline.

Get the app